Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Patent
1995-12-14
1998-04-21
Nutter, Nathan M.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
514 27, 514283, A61K 9127, A01N 4304
Patent
active
057415161
ABSTRACT:
Liposomal formulations having extended circulation time in vivo and increased drug retention are comprised of sphingomyelin and cholesterol and have an acidic intraliposomal pH. The formulations have enhanced stability and thus are used in methods which provide improved drug delivery and more effective treatment. The delivery of ciprofloxacin, and alkaloid drugs, particularly swainsonine, vincristine and vinblastine, is significantly improved.
REFERENCES:
patent: 4837028 (1989-06-01), Allen
patent: 4920016 (1990-04-01), Allen et al.
patent: 4952408 (1990-08-01), Rahman
patent: 5192549 (1993-03-01), Barenolz et al.
patent: 5543152 (1996-08-01), Webb et al.
Weereratne et al., "Toxicity of Sphingomyelin-containing Liposomes after Chronic Injection into Mice," Brit. J. Exp. Pathol. 64:670-676 (1983).
Allen et al., "Chronic Liposome Administration in Mice: Effects on Reticuloendothelial Function and Tissue Distribution," J. Pharmacol. Exp. Therap. 229:267-275 (1984).
Allen et al., "Liver Pathology Accompanying Chronic Liposome Administration in Mouse," Res. Commun. Chem. Pathol. Pharmacol. 50:281-290 (Nov., 1985).
Mayer et al., "Solute Distributions and Trapping Efficiencies Obsered in Freeze-Thawed Multilamellar Vesicles," Biochim. Biophys. Acta 817:193-196 (1985).
Allen et al., "Large Unilamellar Liposomes with Low Uptake into the Reticuloendothelial System," FEBS Lett. 223:42-46 (Oct., 1987).
Allen et al., "Liposomes with Prolonged Circulation times; Factors Affecting Uptake by Reticuloendothelial and Other Tissues," Biochim. Biophys. Acta 981:27-35 (1989).
Mayer et al., "Liposomal Vincristine Preparations Which Exhibit Decreased Drug Toxicity and Increased Activity against Murine L1210 and P388 Tumors," Cancer Res. 50:575-579 (Feb. 1, 1990).
Madden et al., "The Accumulation of Drugs Within Large Unlilamellar Vesicles Exhibiting a Proton Gradient: A Survey," Chem. Phys. Lipids 53:37-46 (1990).
Mayer et al., Characterization of Liposomal Systems Containing Doxorubicin Entrapped in Response to pH Gradients, Biochim. Biophys. Acta 1025:143-151 (1990).
Allen et al., "Lipsomes Containing Synthetic Lipid Derivatives of Poly(ethyleneglycol) Show Prolonged Circulation Half-Lives in Vivo," Biochim. Biophys. Acta. 1066:29-36 (1991).
Allen et al., "Pharmacokinetics of Stealth versus Conventional Liposomes: Effect of Dose," Biochim. Biophys. Acta. 1068:133-141 (1991).
Mayer et al., "Identification of Vesicle Properties that Enhance the Antitumour Activity of Liposomal Vincristine Against Murine L1210 Leukemia," Cancer Chemother. Pharmacol. 33:17-24 (1993).
Grit et al., "Chemical Stability of Liposomes: Implicatioons for their Physical Stability," Chem. Phys. Lipids 64:3-18 (1993).
Boman et al., "Liposomal Vincristine Which Exhibits Increased Drug Retention and Increased Circulation Longevity Cures Mice Bearing P388 Tumors," Cancer Res. 54: 2830-2833 (Jun. 1, 1994).
Hope et al., "Generation of Multilamellar and Unilamellar Phospholipid Vesicles", Chemistry and Physics of Lipids, 40:89-107 (1986).
Bally Marcel B.
Mayer Lawrence D.
Miller James J.
Tardi Paul G.
Webb Murray S.
Inex Pharmaceuticals Corporation
Nutter Nathan M.
LandOfFree
Sphingosomes for enhanced drug delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sphingosomes for enhanced drug delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sphingosomes for enhanced drug delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2055420